Abbott Laboratories Corporation

Other

Sushil G Devare

Suresh M Desai

James M Casey

Julie Yamaguchi

John R Hackett

Robert K Hickman

Catherine A Brennan

Alan M Golden

Stephen H Dailey

Smriti U Mehta

George J Dawson

Jeffrey C Hunt

Robin A Gutierrez

James L Stewart

Richard R Lesniewski

Kevin R Rupprecht

Suzanne L Bode

Billy J Zeck

Jill E Johnson

Donald E Frail

Joan D Tyner

Klara Abravaya

Ning Tang

Virender K Sarin

Larry T Mimms

Jacek J Gorzowski

Wlodzimierz Mandecki

Timothy J Bolling

Priscilla Swanson

Claudia A Esping

Vincent A Varitek, Jr

Anadruzela S Vallari

Barbara J Harris

Shinichi Watanabe

Sheela M George

Mary S Gibadlo

Elizabeth C Necklaws

Ilse I Tribby

John Hackett

Claudia Esping

Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 Group M env polypeptide and (b) further antigen constructs containing additional Group O sequences and especially the gp41 IDR of isolate HAM112. Also claimed are polynucleotide sequences encoding the above, expression vectors comprising the same, host cells transformed thereby, and immunoassay methods and kits utilizing the antigen constructs of the invention.

Antigen constructs useful in the detection and differentiation of antibodies to HIV

Oligonucleotide primer sets, probes, and combinations of the primer sets and probes are provided herein. These reagents are useful for amplifying and detecting HIV-1 target sequences in a test sample.

Amplification and detection reagents for HIV-1

Unique recombinant antigens representing distinct antigenic regions of the Hepatitis C Virus (HCV) genome which can be used as reagents for the detection of antibodies and antigen in body fluids from individuals exposed to HCV. The present invention also provides an assay for detecting the presence of an antibody to an HCV antigen in a sample by contacting the sample with the recombinant antigens. Preferred assay formats include a screening assay, a confirmatory assay, a competition or neutralization assay and an immunodot assay.

Hepatitis C assay utilizing recombinant antigens

The present invention provides a method of synthesizing genes encoding unique HIV-1 and HIV-2 envelope proteins and their fragments, thereby allowing overexpression of these proteins in . The HIV envelope proteins and their fragments have been expressed at high levels as individual proteins or in fusion with other proteins. The HIV envelope proteins thus expressed in can be effectively used for the detection of exposure to HIV as well as the discrimination of HIV-1 and HIV-2.

Synthetic HIV-2 envelope genes containing modifications that lead to optimized expression in bacteria

The present invention provides unique recombinant antigens representing distinct antigenic regions of the Hepatitis C Virus (HCV) genome which can be used as reagents for the detection of antibodies and antigen in body fluids from individuals exposed to HCV. The present invention also provides an assay for detecting the presence of an antibody to an HCV antigen in a sample by contacting the sample with the recombinant antigens. Preferred assay formats include a screening assay, a confirmatory assay, a competition or neutralization assay and an immunodot assay.

The present invention provides a method of synthesizing genes encoding unique HIV-1 and HIV-2 envelope proteins and their fragments, thereby allowing overexpression of these proteins in E. coli. The HIV envelope proteins and their fragments have been expressed at high levels as individual proteins or in fusion with other proteins. The HIV envelope proteins thus expressed in E. coli can be effectively used for the detection of exposure to HIV as well as the discrimination of HIV-1 and HIV-2.

Synthetic DNA derived recombinant HIV antigens

A method of performing a rapid assay for the simultaneous detection and differentiation of the analytes HIV-1 group M. HIV-1 group O and HIV-2 utilizing a sequence specific polypeptide of each analyte as capture reagents. An analytical. device also is provided for performing the method which includes these capture reagents. Also provided is a test kit which includes the analytical device which further can include a positive and negative control.

Rapid assay for simultaneous detection and differentiation of antibodies

Mammalian expression systems for the production of HCV fusion proteins. Such expression systems provide high yields of HCV fusion proteins, and enable the development of diagnostic and therapeutic reagents which contain glycosylated structural antigens and also allow for the isolation of the HCV etiological agent.

Hepatitis C virus fusion proteins

Monoclonal antibodies which specifically bind to either Hepatitis C Virus C-100 protein, Hepatitis C Virus 33C protein and Hepatitis C Virus CORE protein, and hybridomas which produce these monoclonal antibodies. Also provided are methods for using these monoclonal antibodies and assay kits containing these antibodies.

Monoclonal antibodies to hepatitis C virus and method for using same

Growing community of inventors

Northbrook, IL, United States of America

Sushil G Devare